Previous 10 | Next 10 |
First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations Clinical trial enrolling patients across multiple sites in the United States PALO A...
BridgeBio recently merged with Eidos, of which it previously owned 64%. AG10 is Eidos' lead asset. AG10 has strong potential which can be unlocked through the merger. For further details see: BridgeBio's Eidos Merger And Its Rationale
BridgeBio Pharma (BBIO) announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics (EIDX).BridgeBio agreed to acquire all of the outstanding common stock of Eidos it did not already own, representing ~36.3% of outstanding shares, in Octobe...
PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common st...
BridgeBio Pharma (BBIO) has priced its upsized offering of $650M of 2.25% convertible senior notes due 2029 (from $400M) in a private offering.Initial purchasers have an option to purchase up to an additional $97.5M of notes. The conversion rate will initially be 10.3050 shares per $1,000 pri...
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (t...
BridgeBio Pharma (BBIO) plans to offer $400M of convertible senior notes due 2029 in a private offering, and initial purchasers have an option to purchase up to an additional $60M of notes.Final terms of the notes, including the initial conversion rate, interest rate and certain oth...
PALO ALTO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $400 million aggregate pri...
When the market is in a phase of rich valuation, it is tempting to broadly identify the market or these stocks as “overvalued”. Making the distinction between stocks deserving high valuations and those that are overvalued is key, particularly in the current market. T...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve ...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...